Indian Pharma Market - September 2015 Update: relatively slower month

Key Insights for September 2015
  1. September saw growth of 9.90%. The average Growth of IPM since April has been 13.4%.
  2. September witnessed addition of Rs. 774 crore over August-15, the lowest since April -15.
  3. Anti-Infective and Respiratory segments pulled down the growth.
  4. Growth Drivers for the previous months were - 2.3% on account of Volumes growth, 4.7% due to Price Increase and 2.9% due to New Introductions  
  5. Growth registered for the quarter has been 11.7%. its split is as follows - Volumes growth at 4.2%, Price Increase at 4.6% and New Introductions at 2.9%
Major Highlights for Month of September 2015
Overall Highlights
  1. Market clocked Rs. 8626 crore
  2. Growth was 9.9%
Corporate
  1. During previous month, amongst the top 10, Zydus grew by 12.6%, followed by Lupin at 12.4% & Sun at 11.8%
  2. Amongst the top 50, Corporates, 20 crossed the overall market growth
  3. Wockhardt had the highest growth at 42.3% amongst the top 50, followed by Troikaa at 38.2% & AstraZeneca at 37.8 %
  4. 18 Corporates had double more than 10% amongst the top 50
  5. Amongst the 11-20 ranked Corporates, Intas had the highest growth at 27.4%, followed by Micro at 16.7% and Torrent at 16.0%
  6. Amongst the 21-30 ranked Corporates, Wockhardt had the highest growth at 42.3%, followed by MSD 33.1% and Novartis at 9.7%
  7. Amongst the 31-40 ranked Corporates, AstraZeneca had the highest growth at 37.8%, followed by Bharat Serums at 19.1% and Wallace at 19.0%
  8. Amongst the 41-50 ranked Corporates, Troikaa had the highest growth at 38.2%, followed by Fourrts at 9.9% and Allergan at 5.5%
  9. Amongst the 51-60 ranked Corporates, Boehringer grew at 43.4% followed by Corona at 21.5% and Hegde & Hegde at 19.5%
  10. Amongst the 61-70 ranked Corporates, Fresenius Kabi grew at 63.7%, followed by RPG  by 19.4%, and followed by TTK at 16.3%
  11. Troikka gained 50th position among the Corporates on MAT Basis 
Companies
  1. For the previous month, amongst the top 10, Zydus Cadila grew by 12.9%, followed by Abbott HC at 12.5% and Lupin at 12.4%
  2. 20 companies, among the top 50 grew faster than the overall market growth
  3. Amongst the 21-30 ranked Companies, Wockhardt had the highest growth at 42.3%, followed by Zuventus 19.9% and Novartis at 9.7%                                                                                                                                                                                              
Indian V/S MNCs
  1. While Indian companies grew at 9.6%, MNCs grew at 10.7% during previous month
  2. Amongst the top 50 in MNCs, AstraZeneca grew at 37.8%,MSD grew by 33.1% followed by Merck at 16.0%
DPCO, Non DPCO & Non-Scheduled Para 19 Market
  1. The DPCO containing molecules market grew at 2.8%, whereas non-DPCO market grew by 10.9%  & Non -Sch Para 19 Market at 11.5%, resulting in an overall growth of 9.9% during previous month
  2. NLEM & Non- NLEM categories showed  unit growth at 1.2% and 1.1% respectively. The Non-Sch Para 19 segment had 9.0% units growth
Therapy
  1. 12 therapies grew faster than the market growth rate
  2. Among the good performers were Gynaecological grew at 13.4%, Gastrointestinal grew at 12.8% , and Pain & Analgesics grew at 9.0%
  3. Among the laggards were Respiratory Market grew at 4.1%, and Anti-infectives grew at 3.2%
  4. In the chronic segment, Anti-diabetic grew at 18.1% and Cardiac grew at 11.8%
  5. Derma market grew by 12.9% & Urology Market at 12.1%
Regional Dynamics
  1. 13 regions grew faster than the market growth
  2. UP East grew fastest at 20.7%, followed by Haryana at 20.6% and Uttarakhand + UP West  at 18.7%
  3. 4 regions had negative growth in September 2015
Molecules
  1. Amoxycillin + Clavulanic Acid grew at 0.6% whereas Glimepiride + Metformin grew at 11.3% at No 2 position
  2. The Paracetamol grew at 20.3%, Atorvastatin 2.9%, Probiotic Microbes at 19.7%, Cefixime -3.6%, Pantoprazole 7.5%, Montelukast + Levocetrizine at 5.5%, Glimepiride + Metformin + Pioglitazone at 13.7%, Vitamin-D at 22.3%, Hydroquinone + Mometasone + Tretinoin at 12.3%, Voglibose + Metformin + Glimepiride at 42.9%, Rosuvastatin at 22.0%, Protein Supplements at -2.6%, Azithromycin at -7.0%, Calcium Carbonate + Vit D3 market at 18.1%
  3. Carica Papaya segment became Rs. 6 crore on MAT Basis
Brands
  1. Monocef lead the pack with Rs. 34 crore sales, followed by Mixtard, Spasmoproxyvon Plus, Augmentin and Corex during the previous month
  2. Spasmoproxyvon Plus grew at 127.3%, followed by Janumet at 104%, Corex 44% amongst top 10 Brands
  3. Other brands who gained ranks include Rotarix (+133), Mifegest Kit (+110), Meronem (+86), Chymoral Forte (+73), Omez (+50), Trajenta (+44), Betnovate C (+41), Vertin (+40), Janumet (+39), Rantac (+32), Panderm Plus, Istamet (+31), Betnesol (+29), levipil (+28), Spasmoproxyvon Plus (+25), Rosuvas (+24), Shelcal (+16), Dolo (+12), Orofer XT (+11), amongst top 100 Brands over September -14
  4. Caripill moves into top 500 brands for the month of Sep -15
  5. 300th Biggest Brand is Gestofit from Alembic          


New Launches in IPM
  1. Total 253 Brands & 437 SKUs launched in previous month
  2. Top new brands were Vilazine, Lupiheme & Vilano
  3. Biggest New Launches by MNC were Amicolon SB, Stugeron Plus & BHRF


Comments

Post a Comment